Compare Endeavour Silver Corp (EXK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs TG Therapeutics Inc — how do they compare? Endeavour Silver Corp trades at $10.58 (market cap $3.14B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 2.4× Endeavour Silver Corp's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| EXK | TGTX | |
|---|---|---|
Market Cap | $3.14B | $7.64B |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $59.06 |
52-Week Low | $5.31 | $26.94 |
Enterprise Value | $3.14B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXK trades at $10.61, up 3.61% today, with a bullish technical signal from moving averages and a consensus analyst price target of $15.50. Recent Q2 2026 earnings matched estimates at $0.15 per share, while Q1 2026 beat expectations. The company reported strong production growth and secured a $25 million credit facility in August 2026, supporting operational expansion.
Outlook is positive due to rising revenue, improved profitability projected for 2026, and favorable metal prices. Risks include high P/E ratio of 52.95, volatile earnings history, and dependence on commodity markets. Institutional sentiment is bullish with 78.57% buy ratings.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
